Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Transplantation. 2011 Jun 27;91(12):1370–1375. doi: 10.1097/TP.0b013e31821ab9aa

TABLE 2.

Kidney transplant-related immunosuppression and posttransplant outcomes

n (%)
Induction immunosuppression
 None 27 (31.8)
 IL-2 receptor antagonist 14 (16.5)
 Antithymocyte globulin 41 (48.2)
 Anti-CD52 (alemtuzumab) 3 (3.5)
Primary oral immunosuppressant
 TAC/MMF/P 64 (75.0)
 CsA/MMF/P 7 (8.2)
 CsA/SRL/P 2 (2.4)
 SRL/MMF/P 2 (2.4)
 TAC/AZA/P 2 (2.4)
 TAC/SRL/P 1 (1.2)
 TAC/MMF 4 (4.7)
 TAC/P 2 (2.4)
 CsA/P 1 (1.2)
Follow-up (mean±SD, yr) 5.4 (3.4)
Acute rejection, n (%) 13 (15.3)
Polyomavirus (BK)-associated nephropathy 6 (7.1)
SCr at 1 yr post-KTX, median (range), mg/dL 1.3 (0.8–2.4)
Clinical relapse of AAV
 Total group 7/85 (8.2)
 WG group 5/42 (11.9)
 MPA group 2/39 (5.1)
 ANCA-positive at time of KTX 4/29 (13.8)
 ANCA-negative at time of KTX 1/46 (2.2)
 ANCA-unknown at time of KTX 2/10 (20.0)

AZA, azathioprine; CsA, cyclosporine; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; SRL, sirolimus; TAC, tacrolimus; WG, Wegener’s granulomatosis; ANCA, antineutrophil cytoplasmic antibody; KTX, kidney transplantation; IL, interleukin; AAV, ANCA-associated vasculitis.